Inhalant use disorder: Difference between revisions
No edit summary |
Sergekorjian (talk | contribs) |
||
(11 intermediate revisions by 2 users not shown) | |||
Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
Inhalant use disorder is a condition characterized by the intentional misuse of [[inhalant]] substances, typically volatile hydrocarbons, for their psychoactive effects. The DSM-V criteria defines this condition as a classical substance abuse disorder lasting 12 months or more. The prevalence of inhalant use disorder is 200 to 4,000 per 100,000 (0.02 to 0.4%) of the overall population and is more common among individuals 12 to 17 years of age. Psychotherapy and cognitive behavioral therapy are the cornerstones of the treatment of inhalant use disorder.<ref name=DSMV>{{cite book | title = Diagnostic and statistical manual of mental disorders : DSM-5 | publisher = American Psychiatric Association | location = Washington, D.C | year = 2013 | isbn = 0890425558 }}</ref> | |||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
Line 12: | Line 13: | ||
*Inhalant intoxication, without meeting criteria for inhalant use disorder | *Inhalant intoxication, without meeting criteria for inhalant use disorder | ||
*Use of sedating substances | *Use of sedating substances | ||
*Disorders impairing central or peripheral nervous system function | *Disorders impairing central or peripheral [[nervous system]] function | ||
*Disorders of other organ systems<ref name=DSMV>{{cite book | title = Diagnostic and statistical manual of mental disorders : DSM-5 | publisher = American Psychiatric Association | location = Washington, D.C | year = 2013 | isbn = 0890425558 }}</ref> | *Disorders of other organ systems<ref name=DSMV>{{cite book | title = Diagnostic and statistical manual of mental disorders : DSM-5 | publisher = American Psychiatric Association | location = Washington, D.C | year = 2013 | isbn = 0890425558 }}</ref> | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
The prevalence of inhalant use disorder is 200 to 4,000 per 100,000 (0.02 .4%) of the overall population.<ref name=DSMV>{{cite book | +title = Diagnostic and statistical manual of mental disorders : DSM-5 | publisher = American Psychiatric Association | location = Washington, D.C | year = 2013 | isbn = 0890425558 }}</ref> | The prevalence of inhalant use disorder is 200 to 4,000 per 100,000 (0.02 to 0.4%) of the overall population.<ref name=DSMV>{{cite book | +title = Diagnostic and statistical manual of mental disorders : DSM-5 | publisher = American Psychiatric Association | location = Washington, D.C | year = 2013 | isbn = 0890425558 }}</ref> | ||
==Risk factors== | ==Risk factors== | ||
*Conduct disorder | |||
*[[Antisocial personality disorder]] | |||
*Environmental gases inhalation | |||
*Youths with [[behavioral inhibition]]<ref name=DSMV>{{cite book | title = Diagnostic and statistical manual of mental disorders : DSM-5 | publisher = American Psychiatric Association | location = Washington, D.C | year = 2013 | isbn = 0890425558 }}</ref> | |||
==Natural History, Complications and Prognosis== | ==Natural History, Complications and Prognosis== | ||
Poor prognostic factors include: | |||
*Working with industrial gas exposure | |||
*[[Behavioral inhibition]] | |||
*[[Antisocial personality disorder]]<ref name=DSMV>{{cite book | title = Diagnostic and statistical manual of mental disorders : DSM-5 | publisher = American Psychiatric Association | location = Washington, D.C | year = 2013 | isbn = 0890425558 }}</ref> | |||
==Diagnosis Criteria== | ==Diagnosis Criteria== | ||
Line 31: | Line 40: | ||
# There is a persistent desire or unsuccessful efforts to cut down or control use of the inhalant substance. | # There is a persistent desire or unsuccessful efforts to cut down or control use of the inhalant substance. | ||
# A great deal of time is spent in activities necessary to obtain the inhalant substance, use it, or recover from its effects. | # A great deal of time is spent in activities necessary to obtain the inhalant substance, use it, or recover from its effects. | ||
# Craving, or a strong desire or urge to use the inhalant substance. | # [[Craving]], or a strong desire or urge to use the inhalant substance. | ||
# Recurrent use of the inhalant substance resulting in a failure to fulfill major role obligations at work, school, or home. | # Recurrent use of the inhalant substance resulting in a failure to fulfill major role obligations at work, school, or home. | ||
# Continued use of the inhalant substance despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of its use. | # Continued use of the inhalant substance despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of its use. | ||
Line 39: | Line 48: | ||
# Tolerance, as defined by either of the following: | # Tolerance, as defined by either of the following: | ||
a. A need for markedly increased amounts of the inhalant substance to achieve intoxication or desired effect. | :: a. A need for markedly increased amounts of the inhalant substance to achieve intoxication or desired effect. | ||
'''''OR''''' | :: '''''OR''''' | ||
b. A markedly diminished effect with continued use of the same amount of the inhalant substance. | :: b. A markedly diminished effect with continued use of the same amount of the inhalant substance. | ||
Specify the particular inhalant: When possible, the particular substance involved should be named (e.g., “solvent use disorder'’). | ''Specify the particular inhalant:'' When possible, the particular substance involved should be named (e.g., “solvent use disorder'’). | ||
''Specify if:'' | ''Specify if:'' | ||
'''In early remission:''' After full criteria for inhalant use disorder were previously met, none of the criteria for inhalant use disorder have been met for at least 3 months but for less than 12 months (with the exception that Criterion A4, | : '''In early remission:''' After full criteria for inhalant use disorder were previously met, none of the criteria for inhalant use disorder have been met for at least 3 months but for less than 12 months (with the exception that Criterion A4, “[[Craving]], or a strong desire or urge to use the inhalant substance,” may be met). | ||
'''''OR''''' | : '''''OR''''' | ||
'''In sustained remission:''' After full criteria for inhalant use disorder were previously met, none of the criteria for inhalant use disorder have been met at any time during a period of 12 months or longer (with the exception that Criterion A4, “Craving, or a strong desire or urge to use the inhalant substance,” may be met). | : '''In sustained remission:''' After full criteria for inhalant use disorder were previously met, none of the criteria for inhalant use disorder have been met at any time during a period of 12 months or longer (with the exception that Criterion A4, “Craving, or a strong desire or urge to use the inhalant substance,” may be met). | ||
''Specify if:'' | ''Specify if:'' | ||
'''In a controlled environment:''' This additional specifier is used if the individual is in an environment where access to inhalant substances is restricted. | : '''In a controlled environment:''' This additional specifier is used if the individual is in an environment where access to inhalant substances is restricted. | ||
'''Coding based on current severity:''' Note for ICD-10-CM codes: If an inhalant intoxication or another inhalant-induced mental disorder is also present, do not use the codes below for inhalant use disorder. Instead, the comorbid inhalant use disorder is indicated in the 4th character of the inhalant-induced disorder code (see the coding note for inhalant intoxication or a specific inhalant-induced mental disorder). For example, if there is comorbid inhalant-induced depressive disorder and inhalant use disorder, only the inhalant-induced depressive disorder code is given, with the 4th character indicating whether the comorbid inhalant use disorder is mild, moderate, or severe: | : '''Coding based on current severity:''' Note for ICD-10-CM codes: If an inhalant intoxication or another inhalant-induced [[mental disorder ]]is also present, do not use the codes below for inhalant use disorder. Instead, the comorbid inhalant use disorder is indicated in the 4th character of the inhalant-induced disorder code (see the coding note for inhalant intoxication or a specific inhalant-induced mental disorder). For example, if there is comorbid inhalant-induced [[depressive disorder]] and inhalant use disorder, only the inhalant-induced depressive disorder code is given, with the 4th character indicating whether the comorbid inhalant use disorder is mild, moderate, or severe: mild inhalant use disorder with inhalant-induced depressive disorder or a moderate or severe inhalant use disorder with inhalant-induced depressive disorder. | ||
} | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} |
Latest revision as of 14:18, 31 October 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]
Synonyms and keywords: Inhaling vapors; huffing
Overview
Inhalant use disorder is a condition characterized by the intentional misuse of inhalant substances, typically volatile hydrocarbons, for their psychoactive effects. The DSM-V criteria defines this condition as a classical substance abuse disorder lasting 12 months or more. The prevalence of inhalant use disorder is 200 to 4,000 per 100,000 (0.02 to 0.4%) of the overall population and is more common among individuals 12 to 17 years of age. Psychotherapy and cognitive behavioral therapy are the cornerstones of the treatment of inhalant use disorder.[1]
Differential Diagnosis
- Intentional inhalant use, without meeting criteria for inhalant use disorder
- Unintentional inhalant exposure from industrial or accidents
- Inhalant intoxication, without meeting criteria for inhalant use disorder
- Use of sedating substances
- Disorders impairing central or peripheral nervous system function
- Disorders of other organ systems[1]
Epidemiology and Demographics
The prevalence of inhalant use disorder is 200 to 4,000 per 100,000 (0.02 to 0.4%) of the overall population.[1]
Risk factors
- Conduct disorder
- Antisocial personality disorder
- Environmental gases inhalation
- Youths with behavioral inhibition[1]
Natural History, Complications and Prognosis
Poor prognostic factors include:
- Working with industrial gas exposure
- Behavioral inhibition
- Antisocial personality disorder[1]
Diagnosis Criteria
DSM-V Diagnostic Criteria for Inhalant Use Disorder[1]
{{cquote|
A. A problematic pattern of use of a hydrocarbon-based inhalant substance leading to clinically significant impairment or distress, as manifested by at least two of the following, occurring within a 12-month period:
- The inhalant substance is often taken in larger amounts or over a longer period than was intended.
- There is a persistent desire or unsuccessful efforts to cut down or control use of the inhalant substance.
- A great deal of time is spent in activities necessary to obtain the inhalant substance, use it, or recover from its effects.
- Craving, or a strong desire or urge to use the inhalant substance.
- Recurrent use of the inhalant substance resulting in a failure to fulfill major role obligations at work, school, or home.
- Continued use of the inhalant substance despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of its use.
- Important social, occupational, or recreational activities are given up or reduced because of use of the inhalant substance.
- Recurrent use of the inhalant substance in situations in which it is physically hazardous.
- Use of the inhalant substance is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance.
- Tolerance, as defined by either of the following:
- a. A need for markedly increased amounts of the inhalant substance to achieve intoxication or desired effect.
- OR
- b. A markedly diminished effect with continued use of the same amount of the inhalant substance.
Specify the particular inhalant: When possible, the particular substance involved should be named (e.g., “solvent use disorder'’).
Specify if:
- In early remission: After full criteria for inhalant use disorder were previously met, none of the criteria for inhalant use disorder have been met for at least 3 months but for less than 12 months (with the exception that Criterion A4, “Craving, or a strong desire or urge to use the inhalant substance,” may be met).
- OR
- In sustained remission: After full criteria for inhalant use disorder were previously met, none of the criteria for inhalant use disorder have been met at any time during a period of 12 months or longer (with the exception that Criterion A4, “Craving, or a strong desire or urge to use the inhalant substance,” may be met).
Specify if:
- In a controlled environment: This additional specifier is used if the individual is in an environment where access to inhalant substances is restricted.
- Coding based on current severity: Note for ICD-10-CM codes: If an inhalant intoxication or another inhalant-induced mental disorder is also present, do not use the codes below for inhalant use disorder. Instead, the comorbid inhalant use disorder is indicated in the 4th character of the inhalant-induced disorder code (see the coding note for inhalant intoxication or a specific inhalant-induced mental disorder). For example, if there is comorbid inhalant-induced depressive disorder and inhalant use disorder, only the inhalant-induced depressive disorder code is given, with the 4th character indicating whether the comorbid inhalant use disorder is mild, moderate, or severe: mild inhalant use disorder with inhalant-induced depressive disorder or a moderate or severe inhalant use disorder with inhalant-induced depressive disorder.
}